In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am ...

could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a patient who experienced muscle spasms and mylagia.

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Sarepta says that Elevidys can treat up to 80% of all DMD patients - according to the FDA's press release announcing full approval of the gene therapy in June last year: Elevidys is a recombinant ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...